title: Radiofrequency ablation of renal tumors with an expandable multitined electrode: results, complications, and pilot evaluation of cooled pyeloperfusion for collecting system protection.
abstract: The objective of this study was to retrospectively evaluate the results of radiofrequency ablation (RFA) of renal tumors with an impedance-based system using an expandable multitined electrode. Twenty-two patients (30 tumors) were treated with RFA over a 7-year period, percutaneously (16 tumors) or intraoperatively (14 tumors). Follow-up imaging was performed at 1-3, 6, and 12 months and yearly thereafter. Twenty-seven of 30 tumors (19/22 patients) showed no residual tumor on the first imaging control. Two residual tumors were successfully ablated by a second RFA procedure. Our mean follow-up period was 35 months (range, 3-84 months). Two tumors that had been completely ablated based on imaging criteria recurred 11 and 48 months after RFA. One was treated by partial nephrectomy. The other one was not treated because the patient developed bone metastases. One patient had nephrectomy because of an RFA-induced ureteropelvic junction stricture. Nine patients (11 sessions) had a pyeloperfusion of cooled saline during RFA. None developed symptomatic complications, even though in three patients the ablation zone extended to the closest calyx (3-5 mm from the tumor). We conclude that RFA of renal tumors is promising, but serious complications to the collecting system must be taken into consideration. Prophylactic per-procedural cooling of the collecting system is feasible but needs further assessment.
authors.affiliation: Department of Genitourinary and Vascular Imaging, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon 69003, France. olivier.rouviere@netcourrier.com
authors.forename: Olivier
authors.initials: O
authors.lastname: Rouvière
authors.forename: Lionel
authors.initials: L
authors.lastname: Badet
authors.forename: François Joseph
authors.initials: FJ
authors.lastname: Murat
authors.forename: Jean Marie
authors.initials: JM
authors.lastname: Maréchal
authors.forename: Marc
authors.initials: M
authors.lastname: Colombel
authors.forename: Xavier
authors.initials: X
authors.lastname: Martin
authors.forename: Denis
authors.initials: D
authors.lastname: Lyonnet
authors.forename: Albert
authors.initials: A
authors.lastname: Gelet
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D004566:Electrodes; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods; D007431:Intraoperative Complications / Q000517:prevention & control*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010477:Perfusion / Q000379:methods*; D010865:Pilot Projects; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome